Proton therapy for spinal tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot study evaluates the use of proton stereotactic body radiotherapy (SBRT) for patients with nonhematologic spinal metastasis who have complex lesions that cannot be effectively treated with standard photon SBRT. The study aims to improve local control rates by utilizing proton therapy, which may allow for better target coverage while minimizing damage to surrounding organs at risk. Participants will receive a prescribed dose of 30 Gy in 5 fractions, and the study will assess the safety and efficacy of this approach in challenging cases.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Histologic proof or unequivocal cytologic proof of nonhematologic malignancy. This may be obtained from either the primary or any metastatic site.
2. Participants must have radiographic evidence of spinal metastasis on MRI.
3. Participants must have a complex case that is unable to be effectively treated with photon SBRT, defined as inability to develop a photon SBRT plan that achieves adequate coverage (≥80% PTV coverage) with a prescription dose of 30 Gy in 5 fractions. Such cases include:

   1. Extensive paraspinal disease
   2. Reirradiation setting
   3. Epidural extension (Bilsky grade ≥1c)
4. Age ≥ 18 years.
5. Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (Karnofsky \>60%).
6. Patients of childbearing potential (male or female) must practice adequate contraception due to possible harmful effects of radiation therapy on an unborn child.
7. Patients must have the ability to understand and the willingness to sign a written informed consent document.
8. All patients must be informed of the investigational nature of this study and must be given written informed consent in accordance with institutional and federal guidelines.

Exclusion Criteria:

1. Participants may not have a spinal metastases case amenable to standard of care photon SBRT planning techniques that achieve ≥80% PTV coverage with a prescription dose of 30 Gy in 5 fractions.
2. Patients who are unable to receive MRIs will be excluded from the study since MRIs will be critical in treatment planning.
3. Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

Where it's running

• Johns Hopkins Hospital
  Baltimore, Maryland, United States Recruiting

Study contacts

• Principal investigator: Kristin Redmond, MD — Johns Hopkins University
• Study coordinator: Kristin Redmond, MD
• Email: kjanson3@jhmi.edu
• Phone: 410-955-6980

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• NovoTTF-200M and NovoTTF-200A devices to treat refractory spinal metastasis

  This Phase I effort will test whether tumor‑treating fields delivered by the NovoTTF-200M or NovoTTF-200A devices are safe in adults with spinal metastases that have stopped responding to radiation, given alone or with standard systemic therapy.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT06906900

• Adding 177Lu-PSMA-617 to EBRT and short ADT for high-risk localized prostate cancer

  This study tests whether adding a PSMA-targeted therapy before and during standard radiation plus a shorter 6-month hormone therapy is safe and may improve outcomes for men with high-risk localized prostate cancer.

  Recruiting Phase 2 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT07550517

• Precision radiotherapy guided by molecular MRI (APT imaging)

  This project will test whether a special MRI scan called amide proton transfer (APT) imaging can better identify the most aggressive areas of glioblastoma to guide radiotherapy in adults.

  Recruiting Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT07512154

• DNAJB1-PRKACA vaccine plus DRP-104, nivolumab, and ipilimumab for advanced fibrolamellar liver cancer

  A early-stage study tests whether a personalized vaccine plus two immune drugs and a glutamine-blocking agent can safely help people with advanced fibrolamellar liver cancer.

  Recruiting Phase 1 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT07430202

• Ruxolitinib for IEC-HS after CAR-T therapy

  This pilot study tests whether ruxolitinib can help treat IEC-HS that can occur after CAR-T therapy in adults.

  Recruiting Phase 1 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT07424222

• Music therapy for patients with newly diagnosed GBM after chemoradiation

  This study tests whether adding music therapy helps improve quality of life for adults with newly diagnosed glioblastoma who are receiving standard treatment.

  Recruiting Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT07375992

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.